Evaluation of the effect of GLP-1 agonists on quality of bowel preparation for colonoscopy in patients with diabetes
| Autor: | Jose M. Cabral, Nitin Das, Fernando Castro-Pavia, Bahaaeldeen Ismail, Carmen V. Villabona, Toishi Sharma Md |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
education.field_of_study Adenoma medicine.diagnostic_test Colorectal cancer business.industry Endocrinology Diabetes and Metabolism Medical record digestive oral and skin physiology Population Colonoscopy medicine.disease Gastroenterology Confidence interval 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Diabetes mellitus Internal medicine Internal Medicine medicine 030211 gastroenterology & hepatology education business Stroke |
| Zdroj: | Practical Diabetes. 34:167-168 |
| ISSN: | 2047-2897 |
| DOI: | 10.1002/pdi.2110 |
| Popis: | People with diabetes mellitus warrant a greater need for colonoscopy owing to the increased risk of colorectal cancer and autonomic neuropathy. Unfortunately, this population is reported to have a higher proportion of inadequate bowel preparation during colonoscopy, which translates into lower adenoma detection rates and repeat colonoscopies. Glucagon-like peptide-1 (GLP-1) agonists commonly used in the management of diabetes are well known to cause delayed gastrointestinal (GI) transit times, yet it is unknown if they contribute to the higher frequency of inadequate bowel preparation in people with diabetes. Therefore, we conducted a retrospective medical record analysis of type 2 diabetic patients aged 45–75 who had an outpatient colonoscopy between 2012 and 2015. Our patients were taking either Byetta, Victoza or Bydureon and the method of bowel preparation used was polyethylene glycol electrolyte lavage solution. Patients who had a diagnosis of conditions known to cause delayed GI transit times (autonomic neuropathy, GI surgery, stroke and multiple sclerosis) were excluded. The final pool consisted of 126 diabetic patients taking a GLP-1 agonist and a control group of 129 diabetic patients who were not taking this class of medication. The percentage of satisfactory bowel preparations in the group taking a GLP-1 agonist was 92.06% and in the control group was 92.25%. Chi-squared p-value for significant difference between these two groups was p = 1.0 (95% confidence interval −0.066 to 0.069). Hence there were no significant differences in bowel preparation among diabetic patients taking GLP-1 agonists vs the control group; GLP-1 agonists can therefore continually be used according to the current standard protocols for colonoscopy before and after colonoscopy. Copyright © 2017 John Wiley & Sons. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text